Related Experiment Video
Updated: Jul 14, 2026
07:54
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Malignant pleural mesothelioma: current concepts in treatment
Athanasios Tsiouris1, Robin K Walesby
1General and Transplantation Surgery at the Royal Free Hospital, London, UK. athtsiouris@hotmail.com
Nature Clinical Practice. Oncology
|May 31, 2007
Summary
Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos. New treatments are needed as current options offer limited survival and quality of life improvements for this asbestos-related disease.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Malignant pleural mesothelioma (MPM) is a locally aggressive cancer of the pleura.
- A strong link exists between MPM and asbestos exposure, with rising incidence expected.
- Current treatments fail to provide long-term survival or improve quality of life.
Purpose of the Study:
- To review the current therapeutic landscape for malignant pleural mesothelioma.
- To highlight the need for novel treatment strategies due to poor outcomes.
- To discuss ongoing clinical trials investigating chemotherapy, surgery, and radiotherapy.
Main Methods:
- Literature review of current MPM treatment modalities.
- Analysis of the efficacy of chemotherapy, surgery, and radiotherapy.
- Overview of ongoing major clinical trials (EAP, MS01, MARS, SAKK).
Main Results:
- Pemetrexed and cisplatin combination shows the best objective responses in chemotherapy.
- The role of surgery and radiotherapy in MPM treatment remains uncertain due to limited data.
- A multimodal approach is currently considered the standard of care.
Conclusions:
- New therapeutic regimens are urgently required for malignant pleural mesothelioma.
- Multicenter trials are crucial to define the roles of chemotherapy, surgery, and radiotherapy.
- Optimizing MPM treatment necessitates a comprehensive, evidence-based approach.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...